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Abstract
Background: The Eating Disorder Examination – Questionnaire Short (EDE-QS) was developed as a 12-item version
of the Eating Disorder Examination Questionnaire (EDE-Q) with a 4-point response scale that assesses eating
disorder (ED) symptoms over the preceding 7 days. It has demonstrated good psychometric properties at initial
testing. The purpose of this brief report is to determine a threshold score that could be used in screening for
probable ED cases in community settings.
Methods: Data collected from Gideon et al. (2016) were re-analyzed. In their study, 559 participants (80.86% female;
9.66% self-reported ED diagnosis) completed the EDE-Q, EDE-QS, SCOFF, and Clinical Impairment Assessment (CIA).
Discriminatory power was compared between ED instruments using receiver operating characteristic (ROC) curve
analyses.
Results: A score of 15 emerged as the threshold that ensured the best trade-off between sensitivity (.83) and
specificity (.85), and good positive predictive value (.37) for the EDE-QS, with discriminatory power comparable to
other ED instruments.
Conclusion: The EDE-QS appears to be an instrument with good discriminatory power that could be used for ED
screening purposes.
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Background
The Eating Disorder Examination Questionnaire (EDE-Q
[1];), derived from the Eating Disorder Examination (EDE
[2];), is one of the most widely used and extensively vali-
dated self-report instruments for eating disorder (ED)
assessment. However, the lengthy administration time of
the EDE-Q and the 28-day period over which it captures
symptoms may be problematic when monitoring session-
by-session outcomes in the context of clinical practice
and treatment. Consequently, researchers have developed
modified versions of this tool [3]. One such version is the
12-item EDE-QS, which was recently developed employ-
ing Rasch’s analysis among individuals with EDs receiving
specialist treatment [4]. The EDE-QS removes the open-
ended responses to behavioural items and also narrows
the reference timeframe from the past 28-days to the past
7-days. Alongside its brevity, this timeframe was adopted
to improve recall potential, and positions the EDE-QS as a
routine outcome-monitoring instrument for individuals in
treatment to aid clinical decision-making via improved
and regular feedback [5].
The EDE-QS has demonstrated good internal
consistency, test-retest reliability, convergent validity
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and sensitivity in a mixed sample of individuals with
probable ED and individuals probably not having an
ED, recruited from a university and a charity [4]. Its
brevity and psychometric properties provide prelimin-
ary support for the use of the EDE-QS as a screening
tool for people with EDs in community settings. How-
ever, a threshold value was not established for the
EDE-QS questionnaire, as it was not originally devel-
oped as a screening instrument. Cut-off scores are im-
portant for facilitating the detection of individuals
likely to be experiencing threshold EDs and differenti-
ating these individuals from those who are unlikely to
have ED symptoms. Existing instruments (such as the
original EDE-Q) are either too long to be practical to
use for screening purposes, do not capture each dis-
order across the ED spectrum (for instance, SCOFF
does not assess BED symptoms), or have inadequate
psychometric properties in some populations (e.g.
SCOFF in overweight women) [6]. Therefore, the aim
of this brief report was to establish and evaluate a cut-
off point on the EDE-QS that could be utilized by re-
searchers and clinicians when identifying probable ED
cases in community settings.
Method
Participants and procedures
A total of 559 people, who were recruited from a univer-
sity and through a charity that offers support for eating
disorders, participated in the EDE-QS validation part of
the study first reported by Gideon et al. [4]. The same
data are used for the secondary analysis reported in the
current study. The majority of participants were women
(80.86%) aged between 18 and 34 years (92.31%).
Seventy-eight percent of the participants identified as
White and 88.90% had tertiary (post-secondary school)
education. Fifty-four (9.66%) participants self-reported
currently having an ED diagnosis (i.e. they responded
with Yes to the question “Do you currently suffer from
an eating disorder (anorexia nervosa, bulimia nervosa,
binge eating disorder, eating disorder not otherwise spe-
cified)?”). Of these, 7 (13%) met criteria for restrictive
anorexia nervosa (AN-R); two (4%) for binge eating/pur-
ging AN subtype (AN-BP); eight (15%) for bulimia ner-
vosa (BN); 10 (19%) for binge eating disorder (BED); and
27 (50%) for other specified feeding and eating disorders
(OSFED) based on their responses on the EDE-Q and
their Body Mass Index (BMI). Mean BMI in the total
sample was 22.35 (SD = 4.61), with 12% of participants
classified as underweight, 72% as average-weight, 12% as
overweight, and 3% as obese. Underweight individuals
were not excluded from the subsample of participants
who self-reported currently not having an ED diagnosis.
Detailed information about recruitment processes and
data collection have been presented elsewhere [4]. In
brief, an invitation to participate was distributed to a
large university in London, UK, and the study was adver-
tised via the Beat - Beating Eating Disorders website, a
UK’s eating disorder charity that offers support to people
with current or former ED difficulties and their families.
Participants provided informed consent and completed
an online survey.
Measures
Eating disorder examination-questionnaire short
The EDE-QS was developed by Gideon et al. [4] as a 12-
item version of the EDE-Q (see below) with a response
scale ranging from 0 to 3, that captures essential symp-
toms of AN, BN and BED. The response scale was short-
ened during the development of the EDE-QS to reduce
the cognitive demand and because respondents were not
making full use of the 0–6 scale (some original categor-
ies were not used consistently with respondents’ ED se-
verity), as observed in Rasch analysis results [see 4].
Scores of items are summed, ranging from 0 to 36 and
higher scores indicate greater ED symptoms. ED symp-
toms are reported for the preceding seven days. Cron-
bach’s alpha obtained in this sample was .91 [4]
indicating excellent internal consistency.
Ede-q
The most recent version of the full EDE-Q [7] is a 28-
item measure of ED symptoms and behaviors. Scores on
each of four subscales (Restraint, Eating Concerns,
Shape Concerns, Weight Concerns) and a Global score
may be derived from items assessing core attitudinal fea-
tures. Participants provide their answers on a scale from
0 to 6, with higher scores indicating greater frequency
and/or severity of ED psychopathology over the previous
28 days. The EDE-Q has been validated in various clin-
ical and non-clinical samples [8]. Previous studies
showed a cut-off score for “probable” ED amongst young
women of 2.3 (in conjunction with the occurrence of
binge eating and/or excessive exercise) [9], and a clinical
cut-off of a global EDE-Q score ≥ 2.8 [6]. In the current
study sample, Cronbach’s alpha was .96 for the global
score and .84, .86, .93 and .88 for the Restraint, Eating
Concern, Shape Concern, and Weight Concern sub-
scales, respectively.
Scoff
The SCOFF [10] is a 5-item measure used to screen for
EDs in primary care. Items tap into key symptoms of
AN and BN with a dichotomous (Yes/No) response
scale. The number of “Yes” responses are summed to
create a total score, with a score ≥ 2 indicative of an ED.
The SCOFF has been found to have good psychometric
properties in international community samples [11].
Cronbach’s alpha in the current sample was .64 [4].
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Clinical impairment assessment
The CIA (CIA 3.0) [12] was designed to measure
psychosocial impairment associated with key ED fea-
tures in the past 28 days. Sixteen items are answered
on a 4-point Likert-type scale summed to compute
the global score, with higher scores indicating greater
perceived impairment. The CIA has previously been
used for ED instrument validation [13, 14] since clin-
ical impairment has shown to be higher among ED
clinical samples relative to healthy controls [15], thus
supporting the instrument’s criterion validity [16]. The
CIA has robust psychometric properties [12]. In the
present sample, Cronbach’s alpha was .96.
Data analysis
The R package “epiR” was used to obtain sensitivity (the
proportion of true cases correctly identified by the test),
specificity (the proportion of true non-cases correctly
identified by the test), positive predictive values (PPV;
the proportion of individuals with positive test results
who have an ED), and negative predictive values (NPV;
the proportion of individuals with negative test results
who do not have an ED). The PPVs and NPVs depend
upon the prevalence of the disorder (e.g. if the preva-
lence is < 10% then PPV can be < 0.5) thus there is no
defined criterion for classifying PPV or NPV as “accept-
able,” or “good” [17]. The package “pROC” was used to
compute the Area Under the Curve (AUC; the surface
area under the curve which describes the relationship
between sensitivity and specificity) statistic and confi-
dence intervals (CI). AUC can obtain values from 0 to 1,
with AUC of 0.50 classified as non-informative; between
0.50 and 0.70 as less accurate; between 0.70 and 0.90 as
moderately accurate; between 0.90 and 1 as highly accur-
ate; and AUC = 1 is considered as perfect [18]. Two par-
ticipants (0.36%) with missing values in the question
about current ED diagnosis were excluded from the ana-
lyses (their Global EDE-Q scores were in a 30th and
38th percentile, indicating their removal would not
markedly impact analyses as they did not have extreme
results in this variable). Complete data were available for
all other variables. Summation scores are more sensitive
to missing data than other scoring methods [19], but as
there were no missing data for the EDE-QS, summation
was considered to be appropriate for this study. Global
cut-off scores calculated as the average of item scores
are also derived and presented in Table 1 in case of a
necessary use by future researchers or clinicians, al-
though for the simplicity in the following text we
limit our discussion to global summation scores.
Using the self-reported ED diagnosis variable, the
number of true positive, false positive, true negative,
and false negative cases were determined separately
for every possible cut-off score on the EDE-QS, and
for the previously established range of cut-off scores
on the EDE-Q (from 1.3 to 2.9) [20] and all possible
SCOFF scores (from 0 to 5) [21]. Sensitivity and spe-
cificity rates were calculated for each of the possible
cut-off score in these instruments, and PPV and NPV
were also obtained. For the purpose of the current
study, only findings for cut-off scores that yielded the
highest levels of discriminatory parameters are re-
ported, as the aim was to detect a cut-off score with
high sensitivity, specificity and PPV. In addition to
this, discriminatory parameters were also derived
among female participants solely (n = 452).
Table 1 Mean (SD) of clinical impairment, EDE-Q scores, and eating disorder behaviour for self-reported eating disorder cases (n =
54) and non-cases (n = 503) in the current study and normative data reported by Mond et al. (2004)
Current study Normative data
Self-reported ED cases (n=54) Self-reported ED non-cases (n=503) ED cases ED non-cases
Mean (SD) Mean (SD) t Mean (SD) Mean (SD)
Clinical impairment 28.67(12.44) 8.24(8.47) 12.15**
Global EDE-Q 3.99(1.39) 1.67(1.32) 12.25** 3.09(0.83) 1.30(0.96)
Restraint 3.67(1.69) 1.52(1.46) 9.47** 2.65(1.48) 1.19(1.21)
Eating concerns 3.40(1.54) 0.97(1.22) 11.26** 2.02(0.95) 0.49(0.74)
Weight concerns 4.23(1.43) 1.86(1.59) 12.04** 3.68(1.08) 1.49(1.20)
Shape concerns 4.64(1.44) 2.31(1.63) 11.90** 4.01(0.98) 2.03(1.38)
OBE 44.4% 12.1% 4.63** 25.0% 2.2%
SBE 5.5% 9.7% -1.23 25.0% 6.0%
Excessive exercisinga 27.8% 6.4% 3.43* 58.3% 8.2%
Note. ED – eating disorders; OBE – objective binge eating (≥ 4 episodes in the last 28 days); SBE – subjective binge eating (≥ 4 episodes in the last 28 days)
a ≥ 20 times in the last 28 days
* p < .01
** p < .001
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Results
Comparison of ED symptom levels between study
subgroups
In the absence of assignment of “ED case” status on the
basis of clinical interview, preliminary analysis was con-
ducted to confirm the validity of the “clinical” and “non-
clinical” group identification, which was based on self-
reported ED diagnosis. In Table 1, two groups were
compared according to clinical impairment level, EDE-Q
scores, and eating disorder behavior assessed by the
EDE-Q. These include objective binge eating episodes
(eating unusually large amount of food and having sense
of losing control over eating), subjective binge eating
episodes (having sense of losing control over eating
without eating unusually large amount of food), and ex-
cessive exercising as a means of controlling weight or
shape. Normative data for EDE-Q scores and prevalence
of eating disorder behavior were also reported in Table 1
to ease comparison with present findings. As can be
seen, participants with a self-reported ED had markedly
elevated levels of ED symptoms when compared with
the non-ED group, levels comparable to (but higher
than) those of community cases of ED among young
adult women identified by means of interview assess-
ment in previous research.
Comparison between measures
As shown in Fig. 1 and Table 2, the EDE-Q and EDE-
QS demonstrated good, and the SCOFF excellent, dis-
criminatory power according to the AUC statistic
(AUC > .90) [18]. The EDE-Q showed an optimal sensi-
tivity (.80) and specificity (.83) at a cut-off score of 2.8,
where the PPV and NPV reached 33 and 97%, respect-
ively. Similarly, with the cut-off score of ≥2, the SCOFF
obtained a PPV and NPV of 34 and 99%, respectively.
The EDE-QS demonstrated an optimal sensitivity (.83)
and specificity (.85) at a total score cut-off of 15. At this
cut-off, the NPV was very high (98%), as with the EDE-
Q and SCOFF, while the PPV of 37% was higher than
that for the EDE-Q (33%) or SCOFF (34%). Similar
results were observed in the female subsample, with nu-
merical differences in statistics of approximately 0.02
(higher sensitivity and PPV, lower specificity). Also, at a
cut-off score of 15 on the EDE-QS, the proportion of
probable ED cases in the total sample was 21.82%, which
is somewhat lower than the rates yielded by the EDE-Q
(23.26%) and SCOFF (25.58%), and closer to the propor-
tion of participants’ self-reported ED diagnosis (9.66%).
Comparison of alternative EDE-QS cut-off points
An EDE-QS score of 13 (but not 14 or 15) was within 1
SD of the mean score among participants who did not
report an ED diagnosis, indicating that scores above 13
are likely to serve as cut-off points, if guided by sugges-
tions in previous studies [20, 22]. Also, when utilizing
the formula for detection of the criterion of clinical sig-
nificance [23], defined as the mid-point between mean
values of non-cases and cases, the result was 13.97.
However, sensitivity was the same for cut-off points of
14 and 15, while specificity was greater with a cut-off
point of 15. When comparing mean CIA total scores
between self-reported ED cases and non-cases according
to each of these proposed cut-off points, the difference
Fig. 1 Relationship between sensitivity and specificity at different cut-off scores. Black-colored markers indicate cut-off scores of 15, 2.8, and 2 for
EDE-QS, EDE-Q, and SCOFF, respectively
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was greatest with a cut-off point of 15 (Mdiff = 20.05; 14:
Mdiff = 19.32; 13: Mdiff = 18.53).
Discussion
The EDE-QS demonstrated good discriminatory power,
obtaining AUC, sensitivity, specificity and PPV estimates
similar to those of the 28-item EDE-Q used in this study,
and similar values were also reported in a study of young
women in primary care [6]. Hence, reducing the number
of items did not influence this instrument’s ability to dif-
ferentiate between self-reported ED cases and non-cases.
Similar discriminatory parameters where observed be-
tween the EDE-QS and the SCOFF as well, with a higher
specificity but lower sensitivity produced by the EDE-
QS. At the optimal cut-off point for the EDE-QS of 15,
which yielded the best trade-off between sensitivity (.83)
and specificity (.85) and the greatest divergence in clin-
ical impairment between self-reported ED cases and
non-cases, PPV was higher for the EDE-QS than for the
SCOFF (.37 vs .34). A potential advantage of the EDE-
QS is that it provides more information on specific ED
behaviors and their severity, which could be more clinic-
ally useful and hence outweigh the cost of the additional
time taken to complete few more items. For instance,
the EDE-QS captures the frequency of binge eating and
purging behavior, which is important for risk and health
management.
It has been suggested [21] that when establishing cut-
off points for ED screening tools, priority should be
given to maximizing sensitivity (i.e. lowering the criteria
for reaching ED level) rather than specificity, since the
purpose of these instruments is to capture potential ED
cases, the status of which could then be confirmed by
means of further assessment, such as a clinical interview.
Prioritizing sensitivity through the selection of a slightly
lower cut-off point, while conducive to an over-inclusion
of non-cases, would serve to ensure the inclusion of in-
dividuals experiencing or likely to experience clinically
significant impairment associated with ED symptoms
and could therefore be seen as good early intervention
practice [24]. The current findings suggest that a cut-off
point of 15 may be optimal when using the EDE-QS for
screening purposes, although a slightly lower cut-off
point may be preferable if optimizing sensitivity is the
goal.
Limitations and directions for future research
Some limitations should be noted. First, as in most pre-
vious studies of screening measures for ED, men were
under-represented in the current study sample. Import-
antly, previous research has suggested that, when
compared to thresholds established for women, a lower
cut-off score on ED measures may be required to iden-
tify clinically significant ED symptoms in men [25, 26].
As the number of males with EDs in the current study
was insufficient to conduct separate gender segregated
analyses, further research will be needed to identify ap-
propriate cut-off points for the EDE-QS (and other
screening instruments) for men. Second, participants’
age ranged between 19 and 34, calling into question the
representativeness of this group for the general popula-
tion, including adolescents and elderly people. Relatedly,
only 15% were classified as overweight or obese which
might signify the shortfall of participants who experience
regular binge eating episodes. Third, ED cases were self-
reported rather than independently identified which is
why inferences concerning direct application of the
EDE-QS as a screening instrument at this stage are ne-
cessarily tentative. Further directions for future research
hence include validation in general population and pri-
mary care samples using clinical interview as a reference
point. Furthermore, while the fact that the EDE-QS
Table 2 Summary statistics for various global score thresholds on the EDE-Q, EDE-QS (summation/average), and SCOFF
Cut-off Rate of probable ED (%) Se(95%CI) Sp(95%CI) PPV(95%CI) NPV(95%CI) AUC(95%CI)
EDE-Q
2.6 25.94 .85(.73–.93) .80(.77–.84) .32(.24–.40) .98(.96–.99) 88(.84–.93)
2.7 24.87 .83(.71–.92) .81(.78–.85) .32(.25–.41) .98(.96–.99)
2.8 23.26 .80(.66–.89) .83(.79–.86) .33(.25–.42) .97(.95–.99)
EDE-QS
13/1.0 26.83 .87(.75–.95) .80(.76–.83) .31(.24–.39) .98(.96–.99) 89(.84–.93)
14/1.1 23.61 .83(.71–.92) .83(.79–.86) .34(.26–.43) .98(.96–.99)
15/1.2 21.82 .83(.71–.92) .85(.81–.88) .37(.28–.46) .98(.96–.99)
16/1.3 19.50 .81(.69–.91) .87(.84–.90) .40(.31–.50) .98(.96–.99)
SCOFF
2 25.58 .89(.77–.96) .81(.77–.84) .34(.26–.42) .99(.97–.99) .90(.87–.94)
Note. ED eating disorders, Se Sensitivity, Sp Specificity, PPV Positive Predictive Value, NPV Negative Predictive Value, AUC Area Under the Curve, CI
Confidence Interval
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captures ED symptoms over the past 7 days may be
strength in terms of facilitating participant recall, the use
of this relatively short time period - far less than the
period of 3 months specified in formal diagnostic criteria
- underscores the point that the EDE-QS, like the EDE-
Q, is not intended as and should not be used as a diag-
nostic instrument. Lastly, to examine the suitability of
the further use of the EDE-QS as a single-factor measure
of ED psychopathology, additional directions for future
research include employing parallel analysis for examin-
ation of the factor structure since this method has been
shown to be superior to scree-plot analysis [27], that was
used in the initial EDE-QS development study [4].
Conclusion
In conclusion, as well as being a useful instrument for
repeated assessments of people in treatment for an ED,
the EDE-QS may be useful in screening for individuals
likely to have clinically significant ED symptoms in non-
clinical populations. In this study a cut-off score of 15
provided optimal validity coefficients.
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